Skip to main content
In FUTURE 5, ACR50 was a prespecified exploratory end point at Week 16 in a subgroup of biologic-naive patients. No clinical or statistical conclusions can be drawn.1,3In FUTURE 5, biologic-naive patients. No clinical or statistical conclusions can be drawn.1,3

Job code (date)

In FUTURE 5, ACR50 was a prespecified exploratory end point at Week 16 in a subgroup of biologic-naive patients. No clinical or statistical conclusions can be drawn.1,3In FUTURE 5, biologic-naive patients. No clinical or statistical conclusions can be drawn.1,3

Job code (date)

In FUTURE 5, ACR50 was a prespecified exploratory end point at Week 16 in a subgroup of biologic-naive patients. No clinical or statistical conclusions can be drawn.1,3In FUTURE 5, biologic-naive patients. No clinical or statistical conclusions can be drawn.1,3

FUSE code